Comorbid insomnia and obstructive sleep apnea are linked to increased long-term risk for cardiovascular and cerebrovascular ...

Fibrin clot formation represents the culminating step in the coagulation cascade, wherein soluble fibrinogen is converted into insoluble fibrin, creating a structural network essential for haemostasis ...

Novel treatments for immune thrombocytopenia (ITP) and the place of direct oral anticoagulation in children and adults are among the insights in thrombotic disorders that were presented at the 2024 ...

Protein C deficiency is a heritable disorder that compromises the natural anticoagulant system, thereby increasing the risk of thromboembolic events such as deep venous thrombosis, pulmonary embolism ...

Autoimmune disease is often associated with an increased risk of thrombosis by a variety of mechanisms. As diagnostic techniques have advanced, the role of antibodies that target proteins involved in ...

The top panel, designed with BioRender.com, illustrates the process of clot formation and lysis, beginning with platelet aggregation and activation of the coagulation cascade, followed by the ...

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today highlighted recent scientific ...

A silicon-based nanothrombolytic combines clot dissolution with local microenvironment regulation, enhancing safety and efficacy in thrombotic disorders. (Nanowerk News) Thrombotic disorders—such as ...

Encouraging data for CAD-1005 in Phase 2 HIT Study EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic opportunities for 12-LOX inhibition beyond HIT PONTE VEDRA, Fla., ...

Thrombotic disorders—such as ischemic stroke, heart attack, pulmonary embolism, and deep vein thrombosis—are principal contributors to global mortality. However, conventional thrombolytic therapies ...

Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase 2 ...